相关实验视频
Updated: Sep 13, 2025

09:58
Lipidomics and Transcriptomics in Neurological Diseases
Published on: March 18, 2022
3.6K
葡萄糖脂在ALS:洞察疾病机制和临床影响
Thibaut Burg1,2, Ludo Van Den Bosch3,4
1Departement of Neuroscience and Leuven Brain Institute (LBI), KU Leuven - University of Leuven, Campus Gasthuisberg O&N5, Herestraat 49, BP 602, Leuven, 3000, Belgium. thibaut.burg@kuleuven.be.
Molecular neurodegeneration
|July 27, 2025
概括
脂质代谢,特别是甘油脂,在肌缩侧面硬化症 (ALS) 中甚至在症状出现之前就发生了变化. 了解这些变化可能会为这种运动神经元疾病揭示新的治疗点.
科学领域:
- 神经科学是一个神经科学.
- 生物化学 生物化学
- 代谢学 代谢学 代谢学
背景情况:
- 肌缩侧面硬化症 (ALS) 是一种致命的神经退行性疾病,影响运动系统,目前没有治疗方法.
- 在ALS中驱动运动神经元退化的病理机制尚未完全理解.
- 改变的脂质新陈代谢,特别是甘油脂,越来越多地被识别为ALS的进展,甚至在症状前.
研究的目的:
- 审查糖脂在运动系统中的生理作用.
- 总结一下最近关于ALS中的甘氨酸脂变化的发现.
- 探索潜在的病理机制和治疗策略,与ALS中的甘氨酸脂相关.
主要方法:
- 关于ALS中糖脂的研究的文献综述.
- 分析运动神经元和肌肉中糖脂的生理功能.
- 对ALS病变发生过程中脂质代谢失调的证据的评估.
主要成果:
- 甘油脂对细胞膜结构,新陈代谢和运动系统中的信号传递至关重要.
- 在ALS患者和动物模型中观察到甘油脂样本的显著变化.
- 这些脂质变化可能在运动神经元退化之前发生,或有助于运动神经元退化.
结论:
- 葡萄糖脂失调是ALS病理学的一个关键特征.
- 对脂质变化的进一步研究可能会为ALS发现新的治疗途径.
- 解决研究脂质变化的挑战对于推进ALS治疗至关重要.
更多相关视频
相关概念视频
Lysosomal Hydrolases
3.9K
Lysosomes are the site for the degradation of macromolecules and biological polymers released during membrane trafficking events such as secretory, endocytic, autophagic, and phagocytic pathways. The membrane-enclosed area of the lysosome, called the lumen, contains hydrolytic enzymes active in an acidic environment. These acid hydrolases are functional at a pH between 4.5 and 5 and are involved in cellular processes such as cell signaling, energy metabolism, restoration of the plasma membrane,...
3.9K
Alzheimer's Disease: Overview
669
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
669
Amyloid Fibrils
9.9K
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
9.9K
Parkinson's Disease: Overview
710
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
710
Ligand-Gated Ion Channel Receptor: Gating Mechanism
2.6K
Ligand-gated ion channels are transmembrane proteins that play a vital role in intercellular communication and functions of the nervous system. They allow the influx of ions across the membrane once the neurotransmitter binds, allowing the subsequent transmission of electrical excitation across the neurons. Other ligand-gated ion channels, like the γ-aminobutyric acid (GABA) receptor, permit anions like chloride into the cells on the binding of the GABA molecule. Their entry into the cell...
2.6K

